Atmosphere-ph.ru

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Лечебное дело
2020 / N 4

Лекарственно-индуцированная тревога
Е.Ю. Эбзеева, О.Д. Остроумова, Н.А. Шаталова, C.В. Батюкина, А.Г. Комарова

Список литературы

1. Корабельникова Е.А. Современный подход к диагностике и терапии тревожных расстройств. Терапия 2018;7(25):63-8.
2. Психические расстройства в клинической практике. Под ред. Смулевича А.Б. М: МЕДпресс-информ; 2011. 719 с.
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005 Jun;62(6):593-602.
4. American Psychiatric Association. American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C: American Psychiatric Association; 2013. 947 p.
5. Tisdale JE, Miller DA. Drug induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018. 1399 р.
6. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005 Jun;62(6):617-27.
7. Goodwin RD, Stayner DA, Chinman MJ, Wu P, Tebes JK, Davidson L. The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Comprehensive Psychiatry 2002 Jul-Aug;43(4):245-52.
8. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Annals of Medicine 2003;35(1):2-11.
9. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annual Review of Psychology 2002;53:83-107.
10. Huffman JC, Smith FA, Blais MA, Januzzi JL, Fricchione GL. Anxiety, independent of depressive symptoms, is associated with in-hospital cardiac complications after acute myocardial infarction. Journal of Psychosomatic Research 2008 Dec;65(6):557-63.
11. Moser DK, McKinley S, Riegel B, Doering LV, Meischke H, Pelter M, Davidson P, Baker H, Dracup K. Relationship of persistent symptoms of anxiety to morbidity and mortality outcomes in patients with coronary heart disease. Psychosomatic Medicine 2011 Nov-Dec;73(9):803-9.
12. Härter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. European Archive of Psychiatry and Clinical Neuroscience 2003 Dec;253(6):313-20.
13. Guthrie SK, Bostwick JR. Anxiety disorders. In: Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR, editors. Koda-Kimble & Young’s applied therapeutics: the clinical use of drugs. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2013: 1863-99.
14. O’Malley MB, Gleeson SK, Weir ID. Wake-promoting medications: efficacy and adverse effects. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis, MO: WB Saunders; 2011: 527.
15. Roehrs T, Roth T. Medication and substance abuse. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis, MO: WB Saunders; 2011: 1380-9.
16. Drugs that may cause psychiatric symptoms. The Medical Letter in Drugs & Therapeutics 2008 Dec;50(1301-2):100-4.
17. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Safety 2002;25(11):791-809.
18. Piacentino D, Kotzalidis GD, Casale AD, Aromatario MR, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Current Neuropharmacology 2015 Jan;13(1):101-21.
19. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. The American Journal of Psychiatry 2007 Nov;164(11):1648-54.
20. Ziprasidone. Medically reviewed by Drugs.com. Last updated on Feb 20, 2020. Available from: https://www.drugs.com/monograph/geodon.html Accessed 2021 Feb 25.
21. Lea JW, Stoner SC, Lafollette J. Agitation associated with aripiprazole initiation. Pharmacotherapy 2007 Sep;27(9):1339-42.
22. Spiegel DA. Pharmacologic strategies for discontinuing benzodiazepine treatment. Journal of Clinical Psychopharmacology 1999;19(6 Suppl 2):12S-6S.
23. Salzman C. Benzodiazepine dependency: summary of the APA task force on benzodiazepines. Psychopharmacology Bulletin 1990;26:61-2.
24. Keller S, Frishman WH, Epstein J. Neuropsychiatric manifestations of cardiovascular drug therapy. Heart Disease 1999 Sep-Oct;1(4):241-54.
25. Davies SJ, Jackson PR, Ramsay LE, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Archives of Internal Medicine 2003 Mar;163(5):592-600.
26. Lara DR. Caffeine, mental health, and psychiatric disorders. Journal of Alzheimers Disease 2010;20(Suppl 1):S239-48.
27. Vilarim MM, Rocha Araujo DM, Nardi AE. Caffeine challenge test and panic disorder: a systematic literature review. Expert Review of Neurotherapeutics 2011 Aug;11(8):1185-95.
28. Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, Huestis MA. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. The American Journal of Addictions 2014 May-Jun;23(3):234-42.
29. Goodman and Gilman’s: the pharmacological basis of therapeutics. Brunton LL, Chabner BA, Knollmann BC, editors. 12th ed. New York: McGraw-Hill Medical; 2011. 1808 p.
30. Mizuki Y, Suetsugi M, Ushijima I, Yamada M. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Progress in Neuropsychopharmacology & Biological Psychiatry 1997 May;21(4):573-90.
31. Haller CA, Jacob P 3rd, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clinical Pharmacology & Therapeutics 2002 Jun;71(6):421-32.
32. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. New York: Cambridge University Press; 2013.
33. Seeman MV. Psychopathology in women and men: focus on female hormones. The American Journal of Psychiatry 1997 Dec;154(12):1641-7.
34. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Safety 2003;26(5):303-35.
35. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001;47(Suppl 3):32-7; discussion 44-8.
36. Norton JW. Gabapentin withdrawal syndrome. Clinical Neuropharmacology 2001;24(4):245-6.
37. DiBlasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG, Patterson AL, Wake RW, Derweesh IH. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. The Canadian Journal of Urology 2008 Oct;15(5):4249-56; discussion 4256.
38. van Riemsdijk MM, van der Klauw MM, van Heest JA, Reedeker FR, Ligthelm RJ, Herings RM, Stricker BH. Neuro-psychiatric effects of antimalarials. European Journal of Clinical Pharmacology 1997;52(1):1-6.
39. Clattenburg RN, Donnelly CL. Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine. Journal of the American Academy of Child & Adolescent Psychiatry 1997 Nov;36(11):1606-8.
40. Gürkan K, Bilgiç A, Türkoglu S, Kiliç BG, Aysev A, Uslu R. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. Journal of Psychopharmacology (Oxford, England) 2010 Dec;24(12):1810-8.
41. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, Grebow PE. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. Journal of Clinical Pharmacology 1999 Jan;39(1):30-40.
42. Haustein KO, Haffner S, Woodcock BG. A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. International Journal of Clinical Pharmacology & Therapeutics 2002 Sep;40(9):404-18.
43. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004;64(23):2619-27.
44. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001;61(15):2231-42.
45. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. Journal of Clinical Psychopharmacology 2007 Oct;27(5):451-8.
46. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychotherapy & Psychosomatics 2015;84(2):72-81.
47. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. The Annals of Pharmacotherapy 2004 May;38(5):812-6.
48. Cooper MA, Ritchie EC. Testosterone replacement therapy for anxiety. The American Journal of Psychiatry 2000 Nov;157(11):1884.
49. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Archives of Neurology 2002 May;59(5):807-11.
50. Bender B, Milgrom H. Theophylline-induced behavior change in children. An objective evaluation of parents’ perceptions. JAMA 1992 May;267(19):2621-4.
51. Plushner SL. Valerian: Valeriana officinalis. American Journal of Health-System Pharmacy 2000 Feb;57(4):328-35.
52. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998 Nov;280(18):1566-7.
53. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, Williams KE. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics 2007 Jun;29(6):1027-39.
54. US Food & Drug Administration. Varenicline public health advisory. Available from: https://www.fda.gov/Drugs/DrugSafety/Postmarket-Drug Safety Information for Patients and Providers/ucm051136. htm Accessed 2021 Feb 25.
55. Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. Journal of Clinical Oncology 2003 May;21(9):1836-44.
56. Beisecker A, Cook MR, Ashworth J, Hayes J, Brecheisen M, Helmig L, Hyland S, Selenke D. Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients. Psycho-Oncology 1997 Jun;6(2):85-93.
57. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biologocal Psychiatry 2002 Apr;51(8):642-51.
58. Choi SH, Shapiro H, Robinson GE, Irvine J, Neuman J, Rosen B, Murphy J, Stewart D. Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. Journal of Psychosomatic Obstetrics & Gynaecology 2005 Jun;26(2):93-100.
59. Tembe DV, Dhavale A, Desai H, Mane DN, Raut SK, Dhingra G, Sardesai U, Saoji S, Rohra M, Shinde VG, Padsalge M, Paliwal A, Abbasi K, Devnani P, Papinwar S, Phadke S, Mehta H, Bhailume V. Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: a randomized double blind multicentric clinical trial. Neurology Research International 2011;2011:514351.
60. Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. Journal of Clinical Sleep Medicine 2010 Oct;6(5):458-66.
61. Calabrese JR, Frye MA, Yang R, Ketter TA; Armodafinil Treatment Trial Study Network. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. The Journal of Clinical Psychiatry 2014 Oct;75(10):1054-61.
62. Kane JM, D’Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe R. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry 2010 Nov;71(11):1475-81.
63. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews 2013 Feb;(2):CD003409.
64. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. The American Journal of Psychiatry 2010 Jul;167(7):869.
65. Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy & Behavior 2011 Jan;20(1):95-102.
66. Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Klemencic Kozul T, Todorova A, Douiri A, Martin A, Stocchi F, Dietrichs E, Chaudhuri KR; EUROPAR and the IPDMDS non-Motor PD Study Group. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson’s disease: an international multicenter study. Parkinsonism & Related Disorders 2014 Nov;20(11):1231-5.
67. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002 Aug;59(3):408-13.
68. Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014 Feb;28(2):131-45.
69. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, Calmy A. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. Journal of Acquired Immune Deficiency Syndromes 2015 Aug;69(4):422-9.
70. Soler-Palacin P, Aramburo A, Moraga FA, Cabañas MJ, Figueras C. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient. The Pediatric Infectious Disease Journal 2006 Apr;25(4):382.
71. Gatch MB, Nguyen JD, Carbonaro T, Forster MJ. Carisoprodol tolerance and precipitated withdrawal. Drug & Alcohol Dependence 2012 Jun;123(1-3):29-34.
72. Horikawa YT, Udaka TY, Crow JK, Takayama JI, Stein MT. Anxiety associated with asthma exacerbations and overuse of medication: the role of cultural competency. Journal of Developmental & Behavioral Pediatrics 2014 Feb-Mar;35(2):154-7.
73. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94(1-2):60-70.
74. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. European Journal of Neurology 2007 Aug;14(8):900-6.
75. Goldberg JF. Panic attacks associated with the use of topiramate. Journal of Clinical Psychopharmacology 2001 Aug;21(4):461-2.
76. Damsa C, Warczyk S, Cailhol L, Kelley-Puskas AM, Cicotti A, Lazignac C, Andreoli A. Panic attacks associated with topiramate. The Journal of Clinical Psychiatry 2006 Feb;67(2):326-7.
77. Christensen RC, Garces LK. New-onset panic attacks associated with topiramate. Psychiatry (Edgmont) 2006 Jun;3(6):10-8.
78. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ 2015 Jun;350:h2388.
79. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. The American Journal of Psychiatry 2012 May;169(5):491-7.
80. Kunte H, Harms L, Plag J, Hellweg R, Kronenberg G. Acute onset of panic attacks after transdermal estrogen replacement. General Hospital Psychiatry 2014 Sep-Oct;36(5):e7.
81. Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy 2012 Oct;32(10):910-9.
82. Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Doré CJ, Finer N. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. The American Journal of Medicine 2002 Apr;112(5):348-54.
83. Natural Medicines. Therapeutic Research Center (2016). Available from: https://naturalmedicines.therapeuticresearch.com/ Accessed 2021 Feb 25.
84. Rexulti package insert. Rockville, M.D.: Otsuka America Pharmaceutical; July 2015.
85. Vraylar package insert. Parsippany, N.J.: Actavis Pharma; September 2015.
86. Lovick TA. Estrous cycle and stress: influence of progesterone on the female brain. Brazilian Journal of Medical and Biological Research 2012 Apr;45(4):314-20.
87. Tuccori M, Montagnani S, Mantarro S, Capogrosso-Sansone A, Ruggiero E, Saporiti A, Antonioli L, Fornai M, Blandizzi C. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs 2014 Mar;28(3):249-72.
88. Isentress package insert. Whitehouse Station, N.J.: Merck and Co; February 2015.
89. Drugs that may cause psychiatric symptoms. The Medical Letter on Drugs & Therapeutics 2002 Jul;44(1134):59-62.
90. Sullivan GM, Coplan JD, Kent JM, Gorman JM. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biological Psychiatry 1999 Nov;46(9):1205-18.
91. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Science & Practice Perspectives 2002 Jul;1(1):13-20.
92. Wells KB, Golding JM, Burnam MA. Chronic medical conditions in a sample of the general population with anxiety, affective, and substance use disorders. The American Journal of Psychiatry 1989 Nov;146(11):1440-6.
93. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003 Sep;28(9):1694-702.
94. Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H. Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2005 Nov;139B(1):42-4.
95. Domschke K, Maron E. Genetic factors in anxiety disorders. Modern Trends in Pharmacopsychiatry 2013;29:24-46.
96. Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, Ströhle A, Gerlach AL, Alpers GW, Pauli P, Hamm A, Kircher T, Arolt V, Wittchen H, Binder EB, Erhardt A, Deckert J. Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2012 Oct;159B(7):786-93.
97. Weinberger AH, Desai RA, McKee SA. Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders. Drug and Alcohol Dependence 2010 Apr;108(1-2):7-12.
98. Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction 2011 Feb;106(2):418-27.
99. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014 Jan;311(2):155-63.
100. Marques L, Chosak A, Simon NM, Phan DM, Wilhelm S, Pollack M. Rating scales for anxiety disorders. In: Handbook of clinical rating scales and assessment in psychiatry and mental health. Current clinical psychiatry. Baer L, Blais MA, editors. Totowa, NJ: Humana Press; 2010: 37-72.
101. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981 Aug;30(2):239-45.
102. Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgraduate Medical Journal 2001 Feb;77(904):89-93.
103. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? European Archives of Psychiatry and Clinical Neuroscience 2005 Jun;255(3):190-201.
104. Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013 Feb;80(9):800-9.
105. Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015 Mar;350:h1109.
106. Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Archives of General Psychiatry 2003 Feb;60(2):161-8.
107. Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions. Harvard Review of Psychiatry 1997 Nov-Dec;5(4):214-26.
108. Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malaria Journal 2006 Aug;5:74.
109. Perona AA, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase(®). Drug Safety 2016 Jan;39(1):69-78.
110. Синдром прекращения терапии антидепрессантами: диагностика, профилактика и лечение. Здоров’я України 2017;1(40):21. Доступно по: //health-ua.com/article/25775-sindrom-prekrasheniya-terapii-antidepressantami-diagnostika-profilaktika-i-lecheniye Ссылка активна на 25.02.2021.

References

1. Korabelnikova EA. Modern approach to diagnosis and treatment of anxiety disorders. Therapy 2018;7(25):63-8 (In Russian).
2. Mental disorders in clinical practice. Smulevich AB, editor. Moscow 2011; 719 p. (In Russian).
3. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005 Jun;62(6):593-602.
4. American Psychiatric Association. American Psychiatric Association DSM-5 Task Force. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C: American Psychiatric Association; 2013. 947 p.
5. Tisdale JE, Miller DA. Drug induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018. 1399 р.
6. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005 Jun;62(6):617-27.
7. Goodwin RD, Stayner DA, Chinman MJ, Wu P, Tebes JK, Davidson L. The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Comprehensive Psychiatry 2002 Jul-Aug;43(4):245-52.
8. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Annals of Medicine 2003;35(1):2-11.
9. Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R. Emotions, morbidity, and mortality: new perspectives from psychoneuroimmunology. Annual Review of Psychology 2002;53:83-107.
10. Huffman JC, Smith FA, Blais MA, Januzzi JL, Fricchione GL. Anxiety, independent of depressive symptoms, is associated with in-hospital cardiac complications after acute myocardial infarction. Journal of Psychosomatic Research 2008 Dec;65(6):557-63.
11. Moser DK, McKinley S, Riegel B, Doering LV, Meischke H, Pelter M, Davidson P, Baker H, Dracup K. Relationship of persistent symptoms of anxiety to morbidity and mortality outcomes in patients with coronary heart disease. Psychosomatic Medicine 2011 Nov-Dec;73(9):803-9.
12. Härter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. European Archive of Psychiatry and Clinical Neuroscience 2003 Dec;253(6):313-20.
13. Guthrie SK, Bostwick JR. Anxiety disorders. In: Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR, editors. Koda-Kimble & Young’s applied therapeutics: the clinical use of drugs. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2013: 1863-99.
14. O’Malley MB, Gleeson SK, Weir ID. Wake-promoting medications: efficacy and adverse effects.. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis, MO: WB Saunders; 2011: 527.
15. Roehrs T, Roth T. Medication and substance abuse. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 5th ed. St. Louis, MO: WB Saunders; 2011: 1380-9.
16. Drugs that may cause psychiatric symptoms. The Medical Letter in Drugs & Therapeutics 2008 Dec;50(1301-2):100-4.
17. Mitler MM, Hayduk R. Benefits and risks of pharmacotherapy for narcolepsy. Drug Safety 2002;25(11):791-809.
18. Piacentino D, Kotzalidis GD, Casale AD, Aromatario MR, Pomara C, Girardi P, Sani G. Anabolic-androgenic steroid use and psychopathology in athletes. A systematic review. Current Neuropharmacology 2015 Jan;13(1):101-21.
19. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. The American Journal of Psychiatry 2007 Nov;164(11):1648-54.
20. Ziprasidone. Medically reviewed by Drugs.com. Last updated on Feb 20, 2020. Available from: https://www.drugs.com/monograph/geodon.html Accessed 2021 Feb 25.
21. Lea JW, Stoner SC, Lafollette J. Agitation associated with aripiprazole initiation. Pharmacotherapy 2007 Sep;27(9):1339-42.
22. Spiegel DA. Pharmacologic strategies for discontinuing benzodiazepine treatment. Journal of Clinical Psychopharmacology 1999;19(6 Suppl 2):12S-6S.
23. Salzman C. Benzodiazepine dependency: summary of the APA task force on benzodiazepines. Psychopharmacology Bulletin 1990;26:61-2.
24. Keller S, Frishman WH, Epstein J. Neuropsychiatric manifestations of cardiovascular drug therapy. Heart Disease 1999 Sep-Oct;1(4):241-54.
25. Davies SJ, Jackson PR, Ramsay LE, Ghahramani P. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Archives of Internal Medicine 2003 Mar;163(5):592-600.
26. Lara DR. Caffeine, mental health, and psychiatric disorders. Journal of Alzheimers Disease 2010;20(Suppl 1):S239-48.
27. Vilarim MM, Rocha Araujo DM, Nardi AE. Caffeine challenge test and panic disorder: a systematic literature review. Expert Review of Neurotherapeutics 2011 Aug;11(8):1185-95.
28. Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, Huestis MA. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. The American Journal of Addictions 2014 May-Jun;23(3):234-42.
29. Goodman and Gilman’s: the pharmacological basis of therapeutics. Brunton LL, Chabner BA, Knollmann BC, editors. 12th ed. New York: McGraw-Hill Medical; 2011. 1808 p.
30. Mizuki Y, Suetsugi M, Ushijima I, Yamada M. Differential effects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Progress in Neuropsychopharmacology & Biological Psychiatry 1997 May;21(4):573-90.
31. Haller CA, Jacob P 3rd, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clinical Pharmacology & Therapeutics 2002 Jun;71(6):421-32.
32. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 4th ed. New York: Cambridge University Press; 2013.
33. Seeman MV. Psychopathology in women and men: focus on female hormones. The American Journal of Psychiatry 1997 Dec;154(12):1641-7.
34. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Safety 2003;26(5):303-35.
35. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001;47(Suppl 3):32-7; discussion 44-8.
36. Norton JW. Gabapentin withdrawal syndrome. Clinical Neuropharmacology 2001;24(4):245-6.
37. DiBlasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG, Patterson AL, Wake RW, Derweesh IH. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. The Canadian Journal of Urology 2008 Oct;15(5):4249-56; discussion 4256.
38. van Riemsdijk MM, van der Klauw MM, van Heest JA, Reedeker FR, Ligthelm RJ, Herings RM, Stricker BH. Neuro-psychiatric effects of antimalarials. European Journal of Clinical Pharmacology 1997;52(1):1-6.
39. Clattenburg RN, Donnelly CL. Case study: neuropsychiatric symptoms associated with the antimalarial agent mefloquine. Journal of the American Academy of Child & Adolescent Psychiatry 1997 Nov;36(11):1606-8.
40. Gürkan K, Bilgiç A, Türkoglu S, Kiliç BG, Aysev A, Uslu R. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment. Journal of Psychopharmacology (Oxford, England) 2010 Dec;24(12):1810-8.
41. Wong YN, Simcoe D, Hartman LN, Laughton WB, King SP, McCormick GC, Grebow PE. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. Journal of Clinical Pharmacology 1999 Jan;39(1):30-40.
42. Haustein KO, Haffner S, Woodcock BG. A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients. International Journal of Clinical Pharmacology & Therapeutics 2002 Sep;40(9):404-18.
43. Onder G, Pellicciotti F, Gambassi G, Bernabei R. NSAID-related psychiatric adverse events: who is at risk? Drugs 2004;64(23):2619-27.
44. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. Drugs 2001;61(15):2231-42.
45. Goethe JW, Woolley SB, Cardoni AA, Woznicki BA, Piez DA. Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. Journal of Clinical Psychopharmacology 2007 Oct;27(5):451-8.
46. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychotherapy & Psychosomatics 2015;84(2):72-81.
47. Nykamp DL, Fackih MN, Compton AL. Possible association of acute lateral-wall myocardial infarction and bitter orange supplement. The Annals of Pharmacotherapy 2004 May;38(5):812-6.
48. Cooper MA, Ritchie EC. Testosterone replacement therapy for anxiety. The American Journal of Psychiatry 2000 Nov;157(11):1884.
49. Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Archives of Neurology 2002 May;59(5):807-11.
50. Bender B, Milgrom H. Theophylline-induced behavior change in children. An objective evaluation of parents’ perceptions. JAMA 1992 May;267(19):2621-4.
51. Plushner SL. Valerian: Valeriana officinalis. American Journal of Health-System Pharmacy 2000 Feb;57(4):328-35.
52. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998 Nov;280(18):1566-7.
53. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, Williams KE. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics 2007 Jun;29(6):1027-39.
54. US Food & Drug Administration. Varenicline public health advisory. Available from: https://www.fda.gov/Drugs/DrugSafety/Postmarket-Drug Safety Information for Patients and Providers/ucm051136. htm Accessed 2021 Feb 25.
55. Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. Journal of Clinical Oncology 2003 May;21(9):1836-44.
56. Beisecker A, Cook MR, Ashworth J, Hayes J, Brecheisen M, Helmig L, Hyland S, Selenke D. Side effects of adjuvant chemotherapy: perceptions of node-negative breast cancer patients. Psycho-Oncology 1997 Jun;6(2):85-93.
57. Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biologocal Psychiatry 2002 Apr;51(8):642-51.
58. Choi SH, Shapiro H, Robinson GE, Irvine J, Neuman J, Rosen B, Murphy J, Stewart D. Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. Journal of Psychosomatic Obstetrics & Gynaecology 2005 Jun;26(2):93-100.
59. Tembe DV, Dhavale A, Desai H, Mane DN, Raut SK, Dhingra G, Sardesai U, Saoji S, Rohra M, Shinde VG, Padsalge M, Paliwal A, Abbasi K, Devnani P, Papinwar S, Phadke S, Mehta H, Bhailume V. Armodafinil versus modafinil in patients of excessive sleepiness associated with shift work sleep disorder: a randomized double blind multicentric clinical trial. Neurology Research International 2011;2011:514351.
60. Black JE, Hull SG, Tiller J, Yang R, Harsh JR. The long-term tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with treated obstructive sleep apnea, shift work disorder, or narcolepsy: an open-label extension study. Journal of Clinical Sleep Medicine 2010 Oct;6(5):458-66.
61. Calabrese JR, Frye MA, Yang R, Ketter TA; Armodafinil Treatment Trial Study Network. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. The Journal of Clinical Psychiatry 2014 Oct;75(10):1054-61.
62. Kane JM, D’Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe R. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry 2010 Nov;71(11):1475-81.
63. Amato L, Davoli M, Minozzi S, Ferroni E, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. The Cochrane Database of Systematic Reviews 2013 Feb;(2):CD003409.
64. Grosshans M, Mutschler J, Hermann D, Klein O, Dressing H, Kiefer F, Mann K. Pregabalin abuse, dependence, and withdrawal: a case report. The American Journal of Psychiatry 2010 Jul;167(7):869.
65. Torres A, Whitney J, Rao S, Tilley C, Lobel R, Gonzalez-Heydrich J. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy & Behavior 2011 Jan;20(1):95-102.
66. Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Klemencic Kozul T, Todorova A, Douiri A, Martin A, Stocchi F, Dietrichs E, Chaudhuri KR; EUROPAR and the IPDMDS non-Motor PD Study Group. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson’s disease: an international multicenter study. Parkinsonism & Related Disorders 2014 Nov;20(11):1231-5.
67. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002 Aug;59(3):408-13.
68. Abers MS, Shandera WX, Kass JS. Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs 2014 Feb;28(2):131-45.
69. Ford N, Shubber Z, Pozniak A, Vitoria M, Doherty M, Kirby C, Calmy A. Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. Journal of Acquired Immune Deficiency Syndromes 2015 Aug;69(4):422-9.
70. Soler-Palacin P, Aramburo A, Moraga FA, Cabañas MJ, Figueras C. Neuropsychiatric reaction induced by abacavir in a pediatric human immunodeficiency virus-infected patient. The Pediatric Infectious Disease Journal 2006 Apr;25(4):382.
71. Gatch MB, Nguyen JD, Carbonaro T, Forster MJ. Carisoprodol tolerance and precipitated withdrawal. Drug & Alcohol Dependence 2012 Jun;123(1-3):29-34.
72. Horikawa YT, Udaka TY, Crow JK, Takayama JI, Stein MT. Anxiety associated with asthma exacerbations and overuse of medication: the role of cultural competency. Journal of Developmental & Behavioral Pediatrics 2014 Feb-Mar;35(2):154-7.
73. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94(1-2):60-70.
74. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. European Journal of Neurology 2007 Aug;14(8):900-6.
75. Goldberg JF. Panic attacks associated with the use of topiramate. Journal of Clinical Psychopharmacology 2001 Aug;21(4):461-2.
76. Damsa C, Warczyk S, Cailhol L, Kelley-Puskas AM, Cicotti A, Lazignac C, Andreoli A. Panic attacks associated with topiramate. The Journal of Clinical Psychiatry 2006 Feb;67(2):326-7.
77. Christensen RC, Garces LK. New-onset panic attacks associated with topiramate. Psychiatry (Edgmont) 2006 Jun;3(6):10-8.
78. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study. BMJ 2015 Jun;350:h2388.
79. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. The American Journal of Psychiatry 2012 May;169(5):491-7.
80. Kunte H, Harms L, Plag J, Hellweg R, Kronenberg G. Acute onset of panic attacks after transdermal estrogen replacement. General Hospital Psychiatry 2014 Sep-Oct;36(5):e7.
81. Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy 2012 Oct;32(10):910-9.
82. Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB, Crook M, Doré CJ, Finer N. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. The American Journal of Medicine 2002 Apr;112(5):348-54.
83. Natural Medicines. Therapeutic Research Center (2016). Available from: https://naturalmedicines.therapeuticresearch.com/ Accessed 2021 Feb 25.
84. Rexulti package insert. Rockville, M.D.: Otsuka America Pharmaceutical; July 2015.
85. Vraylar package insert. Parsippany, N.J.: Actavis Pharma; September 2015.
86. Lovick TA. Estrous cycle and stress: influence of progesterone on the female brain. Brazilian Journal of Medical and Biological Research 2012 Apr;45(4):314-20.
87. Tuccori M, Montagnani S, Mantarro S, Capogrosso-Sansone A, Ruggiero E, Saporiti A, Antonioli L, Fornai M, Blandizzi C. Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management. CNS Drugs 2014 Mar;28(3):249-72.
88. Isentress package insert. Whitehouse Station, N.J.: Merck and Co; February 2015.
89. Drugs that may cause psychiatric symptoms. The Medical Letter on Drugs & Therapeutics 2002 Jul;44(1134):59-62.
90. Sullivan GM, Coplan JD, Kent JM, Gorman JM. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biological Psychiatry 1999 Nov;46(9):1205-18.
91. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Science & Practice Perspectives 2002 Jul;1(1):13-20.
92. Wells KB, Golding JM, Burnam MA. Chronic medical conditions in a sample of the general population with anxiety, affective, and substance use disorders. The American Journal of Psychiatry 1989 Nov;146(11):1440-6.
93. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 2003 Sep;28(9):1694-702.
94. Hohoff C, McDonald JM, Baune BT, Cook EH, Deckert J, de Wit H. Interindividual variation in anxiety response to amphetamine: possible role for adenosine A2A receptor gene variants. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2005 Nov;139B(1):42-4.
95. Domschke K, Maron E. Genetic factors in anxiety disorders. Modern Trends in Pharmacopsychiatry 2013;29:24-46.
96. Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, Ströhle A, Gerlach AL, Alpers GW, Pauli P, Hamm A, Kircher T, Arolt V, Wittchen H, Binder EB, Erhardt A, Deckert J. Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2012 Oct;159B(7):786-93.
97. Weinberger AH, Desai RA, McKee SA. Nicotine withdrawal in U.S. smokers with current mood, anxiety, alcohol use, and substance use disorders. Drug and Alcohol Dependence 2010 Apr;108(1-2):7-12.
98. Piper ME, Cook JW, Schlam TR, Jorenby DE, Baker TB. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction 2011 Feb;106(2):418-27.
99. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, Hurt RD. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014 Jan;311(2):155-63.
100. Marques L, Chosak A, Simon NM, Phan DM, Wilhelm S, Pollack M. Rating scales for anxiety disorders. In: Handbook of clinical rating scales and assessment in psychiatry and mental health. Current clinical psychiatry. Baer L, Blais MA, editors. Totowa, NJ: Humana Press; 2010: 37-72.
101. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981 Aug;30(2):239-45.
102. Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgraduate Medical Journal 2001 Feb;77(904):89-93.
103. Möller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms? European Archives of Psychiatry and Clinical Neuroscience 2005 Jun;255(3):190-201.
104. Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P, Mahler A, Fuchs G, Jost WH, Chaudhuri KR, Koch R, Reichmann H, Ebersbach G. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013 Feb;80(9):800-9.
105. Thomas KH, Martin RM, Knipe DW, Higgins JP, Gunnell D. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015 Mar;350:h1109.
106. Ströhle A, Romeo E, di Michele F, Pasini A, Hermann B, Gajewsky G, Holsboer F, Rupprecht R. Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Archives of General Psychiatry 2003 Feb;60(2):161-8.
107. Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions. Harvard Review of Psychiatry 1997 Nov-Dec;5(4):214-26.
108. Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malaria Journal 2006 Aug;5:74.
109. Perona AA, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase(®). Drug Safety 2016 Jan;39(1):69-78.
110. Syndrome of discontinuation of antidepressant therapy: diagnosis, prevention and treatment. Health of Ukraine 2017;1(40):21. Available from: //health-ua.com/article/25775-sindrom-prekrasheniya-terapii-antidepressantami-diagnostika-profilaktika-i-lecheniye Accessed 2021 Feb 25.

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]